1-8 of 8
Marcia Belvin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models

Jie Lin, Deepak Sampath, Michelle A. Nannini, Brian B. Lee, Michael Degtyarev, Jason Oeh, Heidi Savage, Zhengyu Guan, Rebecca Hong, Robert Kassees, Leslie B. Lee, Tyler Risom, Stefan Gross, Bianca M. Liederer, Hartmut Koeppen, Nicholas J. Skelton, Jeffrey J. Wallin, Marcia Belvin, Elizabeth Punnoose, Lori S. Friedman, Kui Lin
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1760–1772.
https://doi.org/10.1158/1078-0432.CCR-12-3072
Published: 02 April 2013
View article titled, Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
Open the PDF for Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models in another window
Includes: Supplementary data
Journal Articles

Abstract B14: Inherent resistance to BRAF inhibitors in BRAFV600E colorectal tumors is driven by ligand-dependent activation of the EGFR pathway

Ivana Yen, Bonnie Liu, Hartmut Koeppen, Georgia Hatzivassiliou, Shiva Malek, Kyung Song, Patricia Pacheco, Leanne Berry Ross, Stephen Gould, Stephen Schmidt, Joachim Rudolph, Lori Friedman, Marcia Belvin
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): B14.
https://doi.org/10.1158/1078-0432.MECHRES-B14
Published: 04 March 2013
View article titled, Abstract B14: Inherent resistance to BRAF inhibitors in BRAFV600E colorectal tumors is driven by ligand-dependent activation of the EGFR pathway
Open the PDF for Abstract B14: Inherent resistance to BRAF inhibitors in BRAFV600E colorectal tumors is driven by ligand-dependent activation of the EGFR pathway in another window
Journal Articles

GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo

Jeffrey J. Wallin, Jane Guan, Wei Wei Prior, Leslie B. Lee, Leanne Berry, Lisa D. Belmont, Hartmut Koeppen, Marcia Belvin, Lori S. Friedman, Deepak Sampath
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (14): 3901–3911.
https://doi.org/10.1158/1078-0432.CCR-11-2088
Published: 15 July 2012
View article titled, GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death <em>In Vitro</em> and <em>In Vivo</em>
Open the PDF for GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death <em>In Vitro</em> and <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

Harvey Wong, Laurent Vernillet, Amy Peterson, Joseph A. Ware, Lillian Lee, Jean-Francois Martini, Peiwen Yu, Congfen Li, Geoffrey Del Rosario, Edna F. Choo, Klaus P. Hoeflich, Yongchang Shi, Blake T. Aftab, Ron Aoyama, Sanh Tan Lam, Marcia Belvin, John Prescott
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (11): 3090–3099.
https://doi.org/10.1158/1078-0432.CCR-12-0445
Published: 31 May 2012
View article titled, Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor
Open the PDF for Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor in another window
Includes: Supplementary data
Journal Articles

Abstract B8: Targeting p21-activated kinases in human lung cancer

Christy C. Ong, Adrian M. Jubb, Peter M. Haverty, Wei Zhou, Adrian L. Harris, Marcia Belvin, Lori S. Friedman, Hartmut Koeppen, Klaus P. Hoeflich
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3_Supplement): B8.
https://doi.org/10.1158/1078-0432.12AACRIASLC-B8
Published: 01 February 2012
View article titled, Abstract B8: Targeting p21-activated kinases in human lung cancer
Open the PDF for Abstract B8: Targeting p21-activated kinases in human lung cancer in another window
Journal Articles

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

Carol O'Brien, Jeffrey J. Wallin, Deepak Sampath, Debraj GuhaThakurta, Heidi Savage, Elizabeth A. Punnoose, Jane Guan, Leanne Berry, Wei Wei Prior, Lukas C. Amler, Marcia Belvin, Lori S. Friedman, Mark R. Lackner
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14): 3670–3683.
https://doi.org/10.1158/1078-0432.CCR-09-2828
Published: 14 July 2010
View article titled, Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
Open the PDF for Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models in another window
Includes: Supplementary data
Journal Articles

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

Klaus P. Hoeflich, Carol O'Brien, Zachary Boyd, Guy Cavet, Steve Guerrero, Kenneth Jung, Tom Januario, Heidi Savage, Elizabeth Punnoose, Tom Truong, Wei Zhou, Leanne Berry, Lesley Murray, Lukas Amler, Marcia Belvin, Lori S. Friedman, Mark R. Lackner
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (14): 4649–4664.
https://doi.org/10.1158/1078-0432.CCR-09-0317
Published: 15 July 2009
View article titled, <em>In vivo</em> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
Open the PDF for <em>In vivo</em> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models in another window
Includes: Supplementary data
Journal Articles

Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab

Evelyn Yao, Wei Zhou, Si Tuen Lee-Hoeflich, Tom Truong, Peter M. Haverty, Jeffrey Eastham-Anderson, Nicholas Lewin-Koh, Bert Gunter, Marcia Belvin, Lesley J. Murray, Lori S. Friedman, Mark X. Sliwkowski, Klaus P. Hoeflich
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (12): 4147–4156.
https://doi.org/10.1158/1078-0432.CCR-08-2814
Published: 15 June 2009
View article titled, Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab
Open the PDF for Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab in another window
Includes: Supplementary data